Zobrazeno 1 - 10
of 45
pro vyhledávání: '"G R Granneman"'
Publikováno v:
Clinical Drug Investigation. 21:129-136
To determine the single- and multiple-dose pharmacokinetics of atrasentan, a highly selective endothelin-A receptor antagonist that is currently being investigated for the treatment of prostate cancer and cardiovascular disorders. Phase I, randomised
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14885df03bf1abb008b41c5dee7bb7c8
https://doi.org/10.2165/00044011-200121020-00005
https://doi.org/10.2165/00044011-200121020-00005
Autor:
G. R. Granneman, C. Locke, Kenneth W. Sommerville, L. E. Gustavson, E. E. Samara, T. El-Shourbagy
Publikováno v:
Epilepsia. 39:868-873
Summary: Purpose: In two open-label long-term safety studies, we determined tiagabine (TGB) pharmacokinetics in patients with epilepsy. Methods: In all, 2,147 plasma samples from 5 1 1 patients who participated in the studies were available. The tota
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::244bf03528bc6806fdf49b313b7e4f2e
https://doi.org/10.1111/j.1528-1157.1998.tb01182.x
https://doi.org/10.1111/j.1528-1157.1998.tb01182.x
Autor:
S. W. Boellner, H. J. Guenther, Witt Gf, Kenneth W. Sommerville, L. E. Gustavson, G. R. Granneman
Publikováno v:
American Journal of Therapeutics. 5:73-80
This single-center, open-label study examined the safety and potential effect of tiagabine on valproate pharmacokinetics under steady-state conditions. Twelve adult patients with seizures controlled by an individualized fixed dosage of valproate part
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce1dd5fd081afdb8cb076f3d86825404
https://doi.org/10.1097/00045391-199803000-00004
https://doi.org/10.1097/00045391-199803000-00004
Publikováno v:
Clinical Pharmacokinetics. 35:275-291
Ritonavir is 1 of the 4 potent synthetic HIV protease inhibitors, approved by the US Food and Drug Administration (FDA) between 1995 and 1997, that have revolutionised HIV therapy. The extent of oral absorption is high and is not affected by food. Wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3457e29e1a4d59b9b34d3d1ed736db6a
https://doi.org/10.2165/00003088-199835040-00002
https://doi.org/10.2165/00003088-199835040-00002
Publikováno v:
European Journal of Clinical Pharmacology. 52:223-227
Objective: To study the effect of renal impairment on the pharmacokinetics of sertindole. Methods: A single 4 mg oral dose of sertindole was given to normal subjects ( n = 6) and subjects with various degrees of impaired renal function ( n = 18) clas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::984203c0b60437e2aa7016791b7efb3f
https://doi.org/10.1007/s002280050278
https://doi.org/10.1007/s002280050278
Autor:
G. R. Granneman, Kenneth W. Sommerville, S. W. Boellner, L. E. Gustavson, T. El-Shourbagy, J. X. Qian, H. J. Guenther
Publikováno v:
Neurology. 48:1032-1036
We report an open-label study of 25 children with complex partial seizures that assessed the pharmacokinetics and safety of a single dose of approximately 0.1 mg/kg tiagabine. The children received their usual individualized regimen of one concomitan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771adfd30eb240380dded59f21623eb3
https://doi.org/10.1212/wnl.48.4.1032
https://doi.org/10.1212/wnl.48.4.1032
Autor:
Dale J. Kempf, Martin Markowitz, John M. Leonard, David D. Ho, G R Granneman, Sudthida Vasavanonda, Hongmei Mo, Pauline J. Schipper, Ann Hsu, Chernyavskiy T, Charles A. Boucher, N. Lyons, Niu P, Akhteruzzaman Molla, Korneyeva M, Gao Q, D. W. Norbeck
Publikováno v:
Nature Medicine. 2:760-766
Analysis of the HIV protease gene from the plasma of HIV-infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitor ritonavir. Mutants at valine-82, although insufficient to confe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91510d28e91644b4429041bffa375c72
https://doi.org/10.1038/nm0796-760
https://doi.org/10.1038/nm0796-760
Autor:
John H. Cavanaugh, Walid M. Awni, Louise M. Dubé, G R Granneman, R A Braeckman, Charles Locke
Publikováno v:
Clinical Pharmacokinetics. 29:77-83
In controlled trials involving asthma patients, zileuton - a selective 5-lipoxygenase inhibitor - has significantly improved pulmonary function and reduced symptoms. Since theophylline is frequently prescribed for asthma, we designed a placebo-contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92b0c9a3ca9cfb4f16442d809152f9d
https://doi.org/10.2165/00003088-199500292-00011
https://doi.org/10.2165/00003088-199500292-00011
Publikováno v:
Clinical Pharmacokinetics. 29:1-8
A rapid and sensitive assay was developed for the measurement of plasma concentrations of zileuton racemate, a potent inhibitor of 5-lipoxygenase. Zileuton and its inactive N-dehydroxylated metabolite were extracted from human, monkey, and rat plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4de3b4403d8571618f413d13b95fa882
https://doi.org/10.2165/00003088-199500292-00003
https://doi.org/10.2165/00003088-199500292-00003
Publikováno v:
Clinical Pharmacokinetics. 29:98-104
The effects of zileuton (Abbott-64077) on the pharmacokinetics of sulfasalazine (SASP) and its metabolites, sulfapyridine (SP) and N-acetylsulfapyridine (ASP), were studied in a randomised double-blind placebo-controlled study enrolling 14 healthy ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54fefb009241ae750056e0edc428b0ff
https://doi.org/10.2165/00003088-199500292-00014
https://doi.org/10.2165/00003088-199500292-00014